Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.
Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.
Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment
Read how Multi Radiance Medical’s MR5 ACTIV PRO clearance could reshape non-invasive tennis elbow pain treatment and what risks remain.
Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.
Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
Exilby’s German approval gives chronic pain medicine a rare non-opioid test case. Can Vertanical convert data into adoption?
Can Lungpacer Medical’s AeroPace System change the economics of ventilator recovery?
AeroPace moves into East Coast ICU care as hospitals test whether diaphragm stimulation can shorten ventilator recovery. Read the analysis.
Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?
Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?
HeartBeam’s peer-reviewed ECG data raises the stakes in remote cardiac diagnostics
HeartBeam’s ECG evidence could push chest pain assessment closer to patients. The next test is FDA clarity and clinical trust.
Why Hansa Biopharma’s ConfIdeS trial could reshape kidney transplant desensitization
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.